



Biocon Limited

20th KM Hosur Road

Electronics City

Bangalore 560 100, India

T 91 80 2808 2808

F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

June 13, 2019

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol- BIOCON
---	---

Dear Sir/Madam,

Sub: Investor Presentation on “Biosimilars- The Next Big Global Healthcare Opportunity”.

Ref: Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

With reference to the captioned subject, please find enclosed Investor Presentation.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For **BIOCON LIMITED**

Arund
Dr. Arun S Chandavarkar
CEO & Joint Managing Director
DIN: 01596180

Encl: Investor Presentation



Ahead
of the
curve



Biocon Biologics

A Global Biosimilar Player

Dr. Christiane Hamacher, CEO- Biocon Biologics

13 June 2019


Biosimilars – The Next Big Global Healthcare Opportunity

High investments, quality focus and scale needed to deliver biosimilars across the world

A Biosimilar Is A Biological Product



Large and generally complex molecules




Produced from living organisms




Carefully monitored to ensure consistent quality

A Biosimilar Has No Clinically Meaningful Differences From A Reference Product



Pharmacokinetic and, if needed, pharmacodynamic studies



Immunogenicity assessment



Additional clinical studies as needed

A Biosimilar Is Highly Similar To A Reference Product



Purity



Molecular structure



Bioactivity

The data from these comparisons must show that the biosimilar is highly similar to the reference product.


A Biosimilar Is Approved By FDA After Rigorous Evaluation And Testing By The Applicant



Meet FDA's rigorous standards for approval



Are manufactured in FDA-licensed facilities



Are tracked as part of post-market surveillance to ensure continued safety

Biosimilars – The Next Big Global Healthcare Opportunity

To deliver affordable innovation globally

- For the treatment of severe diseases
- Key to progress towards universal healthcare
- To significantly lessen the financial burden of healthcare systems[#]
- An attractive business opportunity
 - 11 of the 15 Top Selling Drugs in the World are Biologics*
 - \$120 Bn in revenue 2018*



[#] IMS Health – Impact of Biosimilar Competition June 2016

* www.genengnews.com/a-lists/top-15-best-selling-drugs-of-2018/, Biocon Internal Research

Biocon Biologics - Fully Integrated Player For Biosimilars

Getting it right the first time – an early mover

1. One of the broadest pipelines
2. Many firsts to our credit
3. Products commercialized in U.S., Europe, Japan and Most of the World
4. Cost competitive
5. Global scale manufacturing capability
6. Marquee partnerships
7. Innovation in various parts of the value chain



Biocon Biologics - Leveraging Global Trends In Healthcare

Bringing innovation to healthcare

Patient-centricity

1. Funding & payment models
2. Patient ecosystems
3. Policy work



Digital disruption

1. Drug development and manufacturing
2. Digital marketing and distribution



Biocon Biologics – Business Performance in FY19

A landmark year – strong realization in developed and Most of the World markets

- Crossed USD 200 million revenue milestone
- Revenue growth of 97% YoY
- 27% of consolidated Biocon revenue FY19 vs 17% last year
- Profit Before Interest and Tax (PBIT) margin rose to 26% in FY19 vs -2% FY18
- High quality affordable innovation delivered to ~ 2 mio patients



Biocon Biologics - What to Expect In The Next Decade?

Building on the current momentum

- Accelerating the growth path
- Ability to further differentiate and disrupt healthcare
- Further strengthening the broad pipeline
- Leveraging our affordable innovation model & global scale R&D

Only few players might be able to succeed in the Biosimilar market

BIOCON ADVANTAGE

- Competitive Cost
- Fully integrated from Lab to market
- Capacity enhancement aligned with expanding global demand
- Next wave of biosimilars through direct commercialization
- Investing in digital marketing and new technologies across the value chain



Biocon Biologics - Set For Success - A Major Global Player in Biosimilars

A fully integrated player who gets its right the first time

1. Well positioned to further build on our early mover advantage
2. Continued investments in R&D and capacity to build on the early success story
3. Able to innovate to accelerate growth
 - digital disruption
 - patient-centricity






Questions?



Ahead
of the curve

Thank You



www.biocon.com